Alberto Lleó Bisa

Alberto Lleó

Dr. Alberto Lleó is the director of the Memory Unit of the Neurology Department at Hospital de la Santa Creu i Sant Pau.

After obtaining his Medical degree from the University of Barcelona, he completed his specialization in Neurology at Hospital de la Santa Creu i Sant Pau in 2000. Two years later, he obtained his PhD in Medicine at the University of Barcelona and continued his education with a clinical and basic research fellowship on memory and movement disorders at the Massachusetts General Hospital, Boston (2002-2004) where he combined clinical and research tasks.

In his professional career, Dr. Alberto Lleó has combined his clinical activity with translational research projects in the field of dementias with a specific focus on the molecular bases of the disease and biomarker development. Some of his main contributions are the discovery of new genetic alterations in Alzheimer’s disease, the study of the gamma-secretase complex, and the assessment of new chemical biomarkers for Alzheimer’s disease and frontotemporal dementia.

Today, Dr. Alberto Lleó runs a translational group, leads many projects funded by public and private agencies, and collaborates regularly with numerous national and international research groups. He also coordinates the Alzheimer program of CIBERNED (Center for Networked Biomedical Research in Neurodegenerative Diseases). To date, he has authored more than 20 book chapters and over 150 publications in international journals, and his contributions have been awarded by the Spanish Society of Neurology.

Recent Publications

  1. Amyloid-β, Tau, and Cognition in Cognitively Normal Older Individuals: Examining the Necessity to Adjust for Biomarker Status in Normative Data. Bos, I, Vos, SJB, Jansen, WJ et al. Front Aging Neurosci 2018

  2. Cerebrospinal fluid mitochondrial DNA levels in patients with multiple sclerosis. Fissolo, N, Cervera-Carles, L, Villar Guimerans, LM et al. Mult. Scler. 2018

  3. The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics. Bos, I, Vos, S, Vandenberghe, R et al. Alzheimers Res Ther 2018

  4. Clinical Subtypes of Dementia with Lewy Bodies Based on the Initial Clinical Presentation. Morenas-Rodríguez, E, Sala, I, Subirana, A et al. J. Alzheimers Dis. 2018

  5. Distinct Clinical Features and Outcomes in Motor Neuron Disease Associated with Behavioural Variant Frontotemporal Dementia. Cortés-Vicente, E, Turon-Sans, J, Gelpi, E et al. Dement Geriatr Cogn Disord 2018

  6. No supportive evidence for TIA1 gene mutations in a European cohort of ALS-FTD spectrum patients. Baradaran-Heravi, Y, Dillen, L, Nguyen, HP et al. Neurobiol. Aging 2018

  7. Monoaminergic impairment in Down syndrome with Alzheimer's disease compared to early-onset Alzheimer's disease. Dekker, AD, Vermeiren, Y, Carmona-Iragui, M et al. Alzheimers Dement (Amst) 2018

  8. Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease. Mattsson, N, Groot, C, Jansen, WJ et al. Alzheimers Dement 2018

  9. Rare nonsynonymous variants in SORT1 are associated with increased risk for frontotemporal dementia. Philtjens, S, Van Mossevelde, S, van der Zee, J et al. Neurobiol. Aging 2018

  10. A 2-Step Cerebrospinal Algorithm for the Selection of Frontotemporal Lobar Degeneration Subtypes. Lleó, A, Irwin, DJ, Illán-Gala, I et al. JAMA Neurol 2018

  11. White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation. Teunissen, CE, Otto, M, Engelborghs, S et al. Alzheimers Res Ther 2018

  12. Cerebral changes and disrupted gray matter cortical networks in asymptomatic older adults at risk for Alzheimer's disease. Cantero, JL, Atienza, M, Sanchez-Juan, P et al. Neurobiol. Aging 2018

  13. Immune-related genetic enrichment in frontotemporal dementia: An analysis of genome-wide association studies. Broce, I, Karch, CM, Wen, N et al. PLoS Med. 2018

  14. Weight loss in the healthy elderly might be a non-cognitive sign of preclinical Alzheimer's disease. Jimenez, A, Pegueroles, J, Carmona-Iragui, M et al. Oncotarget 2017

  15. Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study. Guerreiro, R, Ross, OA, Kun-Rodrigues, C et al. Lancet Neurol 2018

Search PubMed